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ABSTRACT - To evaluate the question of whether “mixed” bipolar disorder is a 
distinct entity, we compared selected cerebrospinal fluid (CSF) biochemical para- 
meters from patients with bipolar disorder, mixed, to those with mania and major 
depression. Fourteen patients in each category (DSM-111) were studied with regard to 
CSF HVA, SHIAA, sodium, potassium, calcium, and magnesium levels under 
carefully controlled conditions. CSF HVA, SHIAA, and sodium were found to be 
significantly higher in manics than in major depressives. Discriminant analysis of the 
biochemical variables of the mixed affective group identified two biochemically 
distinct and clinically different subgroups of seven patients each, one resembling the 
manic group and the other the major depressive group. These findings suggest that 
mixed affective states do not exist as a separate entity, but are compsed of two 
subgroups obtained from the manic and major depressive categories. 
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The simultaneous existence of manic and depres- 
sive symptoms in affectively disordered patients 
was first described by Kraepelin (l) ,  who called 
this condition a “mixed state” and included it as 
a subcategory of “manic-depressive insanity” (2). 
Kraepelin described six types of mixed affective 
states and emphasized that they often pose con- 
siderable diagnostic difficulties. Since that time, 
this diagnostic entity has generated much contro- 
versy. 
According to the conventional “bipolar model” 
of affective disorders, depression and mania repre- 
sent two extremes of an affective spectrum, with 
euthymia an intermediate condition (2-6). Viewed 
from this perspective, mixed affective states with 
an admixture of manic and depressive symp- 
tomatology should be impossible, as manic and 
depressive syndromes would be diametrically 
opposite conditions and mutually exclusive. Nev- 
ertheless, clinicians continue to encounter affective 
patients whose clinical profile is characterized by 
an admixture of manic and depressive symptoms. 
Perhaps because of such clinical “face validity”, 
this diagnostic category has been included as a 
separate entity in all major international classifica- 
tion systems since the Kraepelin era. Both DSM-I11 
(7) and ICD-9 (8) currently have four-digit de- 
nominations for this category. The existence of 
mixed affective states has prompted certain obser- 
vers (9-12) to emphasize the viability of the “uni- 
polar” or “continuum” model of manic-depressive 
illness, wherein depression represents mild illness 
and mania a more severe manifestation, with mix- 
ed states representing the intermediate “switch 
process”. 
While mixed affective states are of considera- 
ble clinical and theoretical importance, there 
have been few systematic studies of this entity. 
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Most previous investigations in this area have 
been anecdotal observations or single case re- 
ports (1, 13, 14), theoretical discussions (4, 11, 
14-16), studies of its incidence (4, 12), pheno- 
menological descriptions (10, 17) and an evalua- 
tion of lithium resistance in this entity (18). The 
dearth of literature is particularly evident in the 
area of pathophysiological aspects, where the 
only systematic studies have been intensive bio- 
chemical investigations of the “switch process” 
in a few rapidly cycling bipolar patients (10, 19). 
These studies have revealed a functional increase 
of catecholamines prior to  the switch from 
depression to  mania. The present study was con- 
ducted in an effort to  evaluate selected biochemi- 
cal parameters in patients with mixed affective 
states and compare them with those with mania 
and major depression. 
Alterations in the functional activity of brain 
neurotransmitter amines appear to  be involved in 
the pathogenesis of affective disorders. Deficien- 
cies of the monoamines (specifically norepine- 
phrine, dopamine, and serotonin) at central syn- 
apses have been linked with depression, and 
excesses with mania (6, 20-23). Metabolites of 
these CNS neurotransmitters have been measured 
in the cerebrospinal fluid (CSF) as an indirect 
method of assessing central neurochemical func- 
tion. The compounds most often measured are 
the predominant metabolites of norepinephrine, 
dopamine and serotonin (5-HT): 3-methoxy- 
4-hydroxyphenylglycol (MHPG), homovanillic 
acid (HVA), and 5-hydroxyindoleacetic acid 
(5-HIAA), respectively. Over 30 CSF studies in 
affective disorders have been conducted, and as 
recent comprehensive reviews (24, 25) have 
pointed out, the results have not been consistent. 
Nevertheless, CSF HVA levels have generally 
been found to be decreased (26-33) to normal 
(34-38) in depression, and normal (39, 40) to 
increased (33, 35, 37, 41) in mania. Similarly, 
5-HIAA levels have been reported to  be signifi- 
cantly decreased (21, 30, 31, 41, 42) to  normal 
(27-29, 32-36, 38) in depression; and reduced 
(41), normal (35, 42) or increased (33) in mania. 
Several studies of electrolyte (principally the 
cations sodium, potassium, calcium and magne- 
sium) metabolism in affective disorders also have 
been conducted, with inconclusive results. While 
normal conditions appear to  be the general rule 
(43), decreased CSF sodium levels in depression 
compared with mania were reported in one study 
(44). 
The present study was conducted in an effort 
to elucidate the CSF biochemical profile (HVA, 
5-HIAA, sodium, potassium, calcium and mag- 
nesium) of mixed affective states and to  compare 
it with those of mania and major depression. 
MHPG was not assayed because of laboratory 
technical difficulties with its assay at that time. 
The specific aim was to compare mixed affective 
states with mania and major depression and eval- 
uate whether this condition constitutes a distinct 
biochemical entity different from mania and 
major depressive disorder. Another question that 
the study addressed was that of the possible 
clinical subcategorization of the mixed affective 
group and an investigation of the relationship 
between the clinical and biochemical categoriza- 
tion of mixed affective states. To our knowledge, 
this is the first systematic CSF study of mixed 
affective states. 
Material and methods 
Subjects 
Subjects included 42 patients with mood disor- 
ders, 14 each in the categories of mania, major 
depression, and bipolar disorder, mixed. The 
manic group consisted of 10 male and 4 female 
patients aged 28.2 & 8.8 years (mean k SD); the 
major depressive group of 9 men and 5 women 
aged 35.6 -C 9.8 years; and the mixed affective 
group of 8 male and 6 female patients aged 29.4 
f 8.9 years. There were no significant sex-dis- 
tribution differences between the three groups (x’ 
= 0.62; df = 2). Although the patients in the 
major depressive category were older than those 
in the other two categories, this difference was 
not statistically significant (F = 2.50, df = 
2,39). In the major depression group, the 8 uni- 
polar and 6 bipolar subjects were not separated, 
as it has been suggested that there are no signifi- 
cant differences between them with regard to  
these CSF metabolites (33), and because of sam- 
ple cell sizes. 
A comprehensive psychiatric evaluation was 
CSF CORRELATES OF AFFECTIVE STATES 291 
conducted by two psychiatrists and diagnoses 
were based on concordance between independent 
assessments made by them. Diagnoses for all 
patients were made using DSM-111 criteria. All 
subjects clinically required hospitalization for 
treatment of their affective disorder, and were 
inpatients for the period of the study. The sub- 
jects received a detailed physical examination 
and a battery of standard laboratory tests on 
their first day of hospitalization. Individuals 
were excluded from the study if there was evi- 
dence of any major physical illness, alcohol or 
other substance abuse, or contraindication to 
lumbar puncture. All subjects gave written 
informed consent to participate in the study after 
its nature and risks were explained to them. 
None of the patients received any psychotropic 
drugs for at least 2 weeks prior to the lumbar 
puncture. Through hospitalization, all patients 
received a low monoamine diet, and caffeine and 
alcohol were strictly proscribed. 
Methods 
Lumbar punctures took place between 9.00 and 
10.00 a.m. following overnight fasting and at 
least 12 h bed rest. The lumbar punctures were 
performed with a fine needle in the left lateral 
decubitus position in the L4-L5 intervertebral 
space. About 12-13 ml of CSF was collected in 
plypropylene tubes, immediately centrifuged and 
stored frozen in aliquots < -20°C and kept at 
this temperature until analyzed. 
HVA and 5 - H I M  were assayed by the spec- 
trofluorometric technique. While the currently 
more commonly employed gas chromatographic 
(GC)-mass spectrometric (45, 46) and high-per- 
formance Liquid chromatographic (HPLC)-elec- 
trochemical detection (47) techniques are more 
sensitive and specific, HVA and 5-HIAA deter- 
minations using the spectrofluorometric method 
correlate very highly (r  = 0.91) with those 
obtained by the former techniques, and the fluo- 
rometric method is considered adequate for most 
studies (48). HVA was assayed by Anden’s meth- 
od (49) and 5-HIAA by the method of Ashcroft 
& Sharman (50). CSF sodium and potassium 
were measured by the flame-photometric meth- 
od; calcium by Clark & Collip’s fluorometric 
method (51); and magnesium by Schacter’s fluo- 
rometric method (52). 
The Hamilton Depression Rating Scale (53, 54) 
and the Petterson Mania Rating Scale ( 5 5 )  were 
administered to all patients on the evening prior to 
the lumbar puncture; aggregate scores from these 
scales were employed as measures of depressive and 
manic syrnptomatology, respectively. The Petter- 
son/Hamilton aggregate ratio was employed as a 
rough measure of the relative proportion of manic 
Table 1 








Manic Mixed affective 
n = 14 n = 14 
23.7 f 3.9* 
42.8 -C 8.4 
145.9 f 8.4 
20.2 f 10.1 
34.3 f 7.1 
141.8 f 8.8 
2.89 f 0.49 
2.19 f 0.20 
2.21 f 0.20 
3.04 f 0.55 
2.26 2 0.29 
2.24 2 0.14 
Depressed Analysis of variance 
F df P n = 14 
16.9 f 4.3 3.42 2.39 < 0.05 
31.5 f 10.5 5.87 2.39 < 0.05 
137.1 f 9.7 3.08 2.39 0.09 
2.86 f 0.54 0.48 2.39 NS 
2.25 -C 0.20 0.34 2,39 NS 
2.23 f 0.21 0.16 2.39 NS 
‘Values expressed as mean f standard deviation 
Laboratory values for normal controls using same technique: 
CSF HVA 25-35 ng/ml 
CSF 5-HIAA 50-60 ng/ml 
CSF sodium 120-145 mEq/l 
CSF potassium 2.5-4.8 mEq/l 
CSF calcium 2.0-2.5 mEq/l 
CSF magnesium 2.2-2.5 mEq/l 
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to  depressive symptoms and was used to  clinically 
subcategorize the mixed affective group. 
The three groups were initially compared on 
the six biochemical variables using analysis of 
variance (ANOVA). The manic and major 
depressive groups were next compared on these 
biochemical variables using post hoc t-tests, and 
based on differentiating biochemical variables, a 
set of discriminant functions was derived. This 
set of discriminant functions was applied to the 
manic and major depressive groups to  evaluate 
its validity in the classification of affective 
patients. This same set of discriminant functions 
was then applied to  the 14 subjects in the mixed 
affective group in an effort to  dichotomize them. 
The subgroups derived from this analysis were 
next compared with each other, and with the 
manic and major depressive groups separately. 
The biochemical subgroups thus derived were 
compared with the previously obtained clinical 
subgroups to  evaluate the overlap using the chi 
square test. 
Resu I ts 
There were no significant age, sex, height or 
weight differences between the three groups. No 
significant differences were found between the 
Table 2 
Discriminant functions on significant biochemical variables 
Manic Depressive 
~ ~ 
Constant -133.02 -112.42 
HVA 0.46622 0.14606 
5-HIAA 0.46351 0.36406 
Sodium 1.6112 1.5378 
General variance 74408 198240 
n 14 14 
unipolar and bipolar depressed patients, and they 
could therefore be combined and analyzed 
together. Table 1 shows the results for the three 
groups for each of the CSF biochemical para- 
meters. ANOVA revealed significant differences 
in HVA and 5-HIAA levels between the three 
groups, and a trend towards a significant sodium 
difference. The mean HVA, 5-HIAA, and 
sodium levels were all higher in the manic group 
than in the major depressive group; the mixed 
affective group occupied an intermediate posi- 
tion between the two groups on all these three 
biochemical variables. There were no major dif- 
ferences between the groups with respect to  
potassium, calcium, and magnesium levels. 
The manic and major depressive groups were 
next compared on all the CSF biochemical varia- 
bles using post hoc f-tests and were found to  
differ significantly with regard to HVA (t  = 
df = 26, P < 0.001), and sodium ( t  = 2.46, df 
= 26, P < 0.05) levels. Based on these differen- 
tiating biochemical variables, a set of discrimi- 
nant functions was obtained (Table 2). This set 
of discriminant functions was applied to  the 28 
patients in the manic and major depressive 
groups and the subjects classified as manic or 
major depressive based on the discriminant func- 
tion. This process resulted in the correct classi- 
fication of 23 out of 28 patients (x2 = 11.71, 
df = 1, P < 0.001) in these groups. 
The same set of discriminant functions was 
then applied to  the mixed affective group. Dis- 
criminant analysis of the mixed affective group 
identified two subgroups; one was classified as 
manic, and the other classified as major depres- 
sive. Both of these subgroups (the mixed manic 
and the mixed depressive) consisted of 7 patients 
each. These two subgroups were compared and 
4.30, df = 26, P < 0.001), 5-HIAA ( f  = 3.87, 
Table 3 
Comparison of mixed affective subgroups 
SCF biochemical Mixed manic Mixed depressive Two-tailed t-test 
parameters n = 7  n = 7  I df P 
HVA 25.0 f 6.1 15.5 f 4.3 3.10 12 < 0.01 
5 - H I M  39.2 f 6.6 29.3 f 8.3  2.30 12 < 0.05 
Sodium 144.3 f 0.11 139.4 f 6.3 0.92 12 NS 
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were found to  differ significantly with regard to  
the CSF biochemical variables HVA and 
5 - H I M  (Table 3). 
Table 4 shows the comparison of both these 
subgroups with the manic and major depressive 
groups. The mixed manic subgroup did not dif- 
fer from the manic group with regard to  any of 
the biochemical variables, but differed signifi- 
cantly from the major depressive group in terms 
of HVA, with a tendency towards significant 
difference with regard to  5 - H I M  and sodium. 
Similarly, the mixed depressive subgroup did not 
differ from the major depressive group on any of 
the biochemical parameters; but it differed sig- 
nificantly from the manic group with regard to 
HVA and 5 - H I M ,  with a tendency towards a 
significant difference with regard to  sodium. 
The two mixed affective subgroups were next 
compared with regard to  their clinical parameters 
(Table 5) ,  using the Hamilton and Petterson 
Table 4 
Comparison of mixed affective subgroups with manic and depressive groups by two-tailed t-test 
Manic Depressive 
n = 14 n = 14 
t df P t df P 
Mixed manic 
n = 7  HVA 0.56 19 NS 3.47 19 < 0.01 
5-HIAA -0.95 19 NS 1.71 19 0.10 
Sodium -0.37 19 NS 1.47 19 0.15 
.Mixed depressive 
n = 7  HVA -4.3 19 < 0.005 -0.69 19 NS 
5-HIAA -3.4 19 < 0.01 -0.49 19 NS 
Sodium -1.7 19 0.09 0.55 19 NS 
Thus the mixed manic subgroup was not different from the manic group, but differed from the depressive group with regard to HVA 
and showed a tendency towards significant differences in terms of 5-HIAA and sodium. Similarly, the mixed depressive subgroup did 
not differ from the depressive group, but differed from the manic group in terms of HVA and 5 - H I M ,  and showed a tendency 
towards a significant difference with regards to sodium. 
Table 5 
Clinical parameters of mixed affective subgroups 
Mixed manic Mixed depressive Two-tailed t-test 
n = 7  n = 7  t df P 
Mean Hamilton 23.3 23.9 0.44 12 NS 
Mean Petterson 26.0 21.2 3.91 12 < 0.001 
Mean Petterson/Hamilton ratio 1.14 0.86 2.36 12 < 0.05 
Table 6 
Relationship between clinical and biochemical subcategorization of mixed affective states 
Biochemical mixed manic Biochemical mixed depressive 
Clinical mixed manic I 2 
Clinical mixed depressive 0 5 
chi square = 8.29 df = I P < 0.005 
The Petterson/Hamilton ratio of 0.85 was used as the cut-off point t o  clinically subcategorize mixed affective states, with 
subjects having a Petterson/Hamilton ratio of < 0.85 being classified as depressive, and those with a ratio > 0.85 being 
clinically classified as manic. 
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aggregate scores as measures of depressive and 
manic symptomatology, respectively. The Petter- 
son/Hamilton ratio was employed as a crude 
measure of the ratio of manic to depressive 
symptomatology in each mixed affective patient. 
The two subgroups differed significantly with 
respect to the Petterson aggregate score and the 
Petterson/Hamilton ratio. 
Based on the Petterson/Hamilton ratio, the 
mixed affective group was then subcategorized 
clinically. A Petterson/Hamilton aggregate ratio 
of 0.85 yielded the best clinical division between 
the two subgroups, with subjects having a ratio 
of > 0.85 being classified as “clinically mixed 
manic”, and patients with a ratio of < 0.85 
being classified as “clinically mixed depressive”. 
Table 6 shows the relationship between the bio- 
chemical and clinical subcategorization of mixed 
affective states. All seven mixed affective sub- 
jects who were biochemically classified as manic 
were also clinically so classified. Of the mixed 
affective patients biochemically classified as 
major depressive, five were clinically so classified 
while two were classified as clinically manic. 
These data provided a clinical validation of the 
biochemical subcategorization of mixed affective 
states. 
Discussion 
Our finding of normal CSF HVA levels in mania 
is consistent with most previous studies (39, 40), 
as is the finding of decreased CSF HVA in major 
depression (26-33). Similarly, our finding of 
reduced 5-HIAA levels in both mania and major 
depression is also consistent with those of most 
studies (21, 30, 31, 41, 42), with 5-HIAA levels 
significantly lower in major depression than in 
mania. While the CSF sodium levels were in the 
normal range in both mania and depression, as 
most commonly found (43), they were signifi- 
cantly lower in the depressive group than in the 
manic group. These results are consistent with 
the widely accepted view that disturbances in the 
CSF turnover of dopamine and serotonin, as 
reflected in the CSF levels of their metabolites 
HVA and 5-HIAA (respectively), may play a 
major role in the pathogenesis of affective disor- 
ders. The finding of lower CSF levels of sodium 
in depression than in mania is consistent with the 
hypothesis of a low rate of turnover of sodium 
by the nervous system in depressed patients (43), 
which was based on the finding of a low transfer 
rate of sodium from blood to CSF (56). The 
finding of normal CSF potassium, calcium, and 
magnesium levels, which were similar in both 
groups, is consistent with most previous reports 
(43). It should be noted that the 3 groups did not 
differ significantly with regard to  such poten- 
tially confounding variables as age, sex, height, 
and weight. 
The discriminant function derived from the 
differentiating biochemical variables correctly 
classified 23 out of 28 subjects in the manic and 
major depressive groups, suggesting that this 
technique is significantly accurate in the classi- 
fication of affective patients as manic or depres- 
sive. This discriminant function subcategorized 
the mixed affective group into manic and depres- 
sive subgroups, each consisting of 7 patients, 
which differed significantly from one another 
with regard to HVA and 5-HIAA. Furthermore, 
the mixed manic subgroup did not differ from 
the original manic group, but differed signifi- 
cantly from the depressive group; similarly the 
mixed depressive subgroup resembled the depres- 
sive group, but differed significantly from the 
manic group. The two mixed affective subgroups 
clinically differed with regard to the ratio of 
manic to depressive symptomatology, and the 
clinical subcategorization of the mixed affective 
group coincided with the biochemical categoriza- 
tion in 12 out of 14 mixed affective patients. 
These findings do not support the view of 
mixed affective states as a distinct homogeneous 
entity. Instead, they suggest that mixed affective 
states constitute a heterogeneous grouping, com- 
prised of patients derived from the manic and 
major depressive categories (respectively). This 
conclusion is supported by a recent study of 
cerebral metabolic rates in mood disorders (57), 
which found a metabolic rate dichotomy between 
mania and depression, with the three mixed 
affective patients in the study showing a meta- 
bolic pattern similar to  that of the depressed 
group. 
The finding that mixed affective states do not 
exist as a separate entity, but are best viewed as 
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either manic or depressed, removes one of the 
strongest criticisms against the bipolar model and 
eliminates the need for elaborate models to 
explain their existence. While Court (1 1, 15) pos- 
tulated a “unipolar” model, with depression, 
mixed states and mania being on a continuum, 
and merely reflecting different severities of ill- 
ness, Nunn (4) hypothesized that mixed affective 
states represented a superimposition on hypo- 
mania of a “second kind of depression”, or the 
development of schizophrenia in the course of a 
manic-depressive illness. Himmelhoch (14, 18) 
suggested that mixed affective states occur either 
in severely ill, continuum-model, manic depres- 
sive patients, or in “true bipolar patients” whose 
illness was complicated by a second neuro- 
psychiatric condition such as sedative abuse or 
epileptic changes. Thus, the observation that 
mixed affective states do not exist separately, 
strongly suggests that the unipolar model does 
not represent a viable conceptualization of the 
nature of manic-depressive illness, since this 
model predicts and is based on the existence of 
such states. This finding also eliminates the need 
to devise other elaborate models to explain mixed 
affective states. While it will continue to  be both 
interesting and important to investigate why 
some patients exhibit mixed affective pheno- 
menology and others do not, these data suggest 
that it seems unlikely that the answer resides in 
the existence of mixed affective states as a sepa- 
rate entity, distinct from mania and major 
depression. 
The clinical implication of these findings is 
that mixed affective states are best treated as 
either manic or depressed. Although their clinical 
subcategorization is difficult, our Pet tersod 
Hamilton aggregate ratio findings suggest that 
this subcategorization really exists. Clearly, bet- 
ter instruments to  make this clinical distinction 
need to be devised. It has been suggested that 
mixed affective states respond poorly to  treat- 
ment and represent a treatment-resistant con- 
dition (1, 12, 18, 58). Perhaps this may be 
attributable to  inappropriate treatment of this 
condition because of a failure to separate this 
group into its predominant manic or depressive 
subgroup and treat accordingly. This hypothesis 
merits testing. 
Several methodological issues deserve com- 
ment. Our inability to  assay MHPG is a major- 
shortcoming of this study. While the spec- 
trofluorometric technique for the assay of HVA 
and 5-HIAA is less sensitive than newer meth- 
ods, it correlates well with them and is consid- 
ered adequate for most studies (48). The unipolar 
and bipolar depressed subjects were analyzed 
together, as no significant differences were found 
between them. In particular, it has been reported 
that there is no significant difference between 
them with regard to  the three CSF monoamine 
metabolites (33). The probenecid technique was 
not employed, as it has been suggested that 
instead of removing a source of variance in CSF 
metabolite studies, this technology introduces 
new and intriguing complexities (59). Finally, 
replication of the discriminant function would be 
desirable. 
Although the findings of this study clearly 
need to be replicated and extended, measuring 
other biochemical variables (especially MHPG), 
and employing more sophisticated methods of 
assay, the results of this study indicate that 
mixed affective states do not exist as a separate 
entity and are actually composed of two sub- 
groups derived from the major depressive and 
manic categories, respectively. 
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